For research use only. Not intended for human consumption, clinical use, or veterinary application.
Introduction to Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), a 44-amino acid peptide produced by the hypothalamus. Tesamorelin consists of the full 44-amino acid sequence of endogenous GHRH with a trans-3-hexenoic acid group conjugated to its N-terminus, a modification that confers greater stability against dipeptidyl peptidase IV (DPP-IV) degradation compared to native GHRH. This structural feature has made it a valuable tool in research examining the growth hormone (GH) / insulin-like growth factor-1 (IGF-1) axis.
Mechanism of Action
Tesamorelin binds to and activates GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the pulsatile release of endogenous growth hormone. Unlike exogenous GH administration, this mechanism preserves the physiological feedback regulation of the GH/IGF-1 axis, including somatostatin-mediated inhibition. Key downstream effects observed in research models include:
- Increased pulsatile GH secretion
- Elevated circulating IGF-1 levels
- Modulation of lipid metabolism, particularly visceral adipose tissue dynamics
- Potential effects on cognitive function via IGF-1 signaling in the central nervous system
Areas of Preclinical and Clinical Research
Metabolic and Adipose Tissue Research
Tesamorelin has been studied extensively in the context of visceral adiposity. Clinical research has demonstrated significant reductions in visceral adipose tissue (VAT) in specific patient populations, an effect attributed to GH-mediated lipolysis. Preclinical models continue to explore the molecular mechanisms underlying these metabolic effects, including interactions with adipokine signaling and insulin sensitivity pathways.
Cognitive and Neurological Research
Emerging research has examined the relationship between the GH/IGF-1 axis and cognitive function. Some studies have investigated Tesamorelin's potential to influence memory and executive function, with proposed mechanisms involving IGF-1's neurotrophic effects and its role in hippocampal neurogenesis. This remains an active and evolving area of investigation.
Body Composition Research
Beyond visceral fat, researchers have examined Tesamorelin's effects on lean body mass, bone mineral density, and overall body composition in various experimental models. GH's anabolic effects on muscle protein synthesis and its interactions with IGF-1 are central to this line of inquiry.
Cardiovascular Markers
Some research programs have assessed the impact of GHRH analog administration on cardiovascular risk markers, including triglyceride levels, carotid intima-media thickness, and inflammatory biomarkers, given the known relationships between GH deficiency and cardiovascular risk.
Research Considerations
Tesamorelin's activity is dependent on intact pituitary function, as it acts upstream of GH secretion. Researchers should account for baseline GH/IGF-1 status in experimental designs. The peptide's relatively short half-life in biological systems, even with the N-terminal modification, is an important pharmacokinetic consideration. Stability under various storage and reconstitution conditions should be validated for each research application.
Availability for Research
GEL Labs offers Tesamorelin 10mg and Tesamorelin 5mg as research-grade compounds for qualified laboratory use. All products are intended strictly for in vitro and preclinical research purposes.
Explore our complete range of RUO Research Reagents for additional compounds supporting your research program.
References: Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. | Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Eur J Endocrinol. 2015;172(1):R1-R12.